search
Back to results

Trial of Tian Jiu Therapy for Allergic Rhinitis

Primary Purpose

Allergic Rhinitis (AR)

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
herbal patches of Tian Jiu group
placebo patches of placebo-control group
Sponsored by
Hong Kong Baptist University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Allergic Rhinitis (AR)

Eligibility Criteria

3 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Positive skin prick tests
  • High circulating levels of allergen-specific IgE antibody detected by a specific blood test for allergy called radioallergosorbent test (RAST)]
  • Clinical history or allergen to have been identified
  • Nasal provocation (test)

Exclusion Criteria:

  • Allergic asthma, moderate to severe atopic dermatitis, autoimmune disorders, severe chronic inflammatory diseases, history of anaphylactic reactions, hypersensitivity to cetirizine or related drugs, specific immunotherapy during the past 3 years or planned in the next 2 years, pregnancy or breastfeeding.

Sites / Locations

  • Hong Kong Baptist University Chinese Medicine Clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Sham Comparator

No Intervention

Arm Label

Tian Jiu group

Placebo-control group

Waitlist-control group

Arm Description

The TJ group will undergo a 4-week treatment with herbal patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in the TJ group will be treated with herbal patches of Tian Jiu group on five acupoints on the back.

The placebo-control group will undergo a 4-week treatment with placebo patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in this group will be treated with placebo patches of placebo-control group on the same acupionts as the TJ group.

The waitlist-control group will receive no treatment during the first 4 weeks but, beginning with the 5th week this group will receive TJ treatment for four weeks as compensatory.

Outcomes

Primary Outcome Measures

Change of total nasal symptom score
The change in the weekly average of total nasal symptom score (TNSS) recorded in participants' diaries from baseline( Week 0) to end of the treatment( Week 4)and post-treatment follow-up ( Week 8)

Secondary Outcome Measures

Change of the Rhinitis Quality of Life Questionnaire (RQLQ)
The change in symptoms will be measured using the Rhinitis Quality of Life Questionnaire (RQLQ), by comparing the baseline( Week 0) with the scores within treatment (Week 2, 3), end of treatment( Week 4) and post-treatment follow-up ( Week 8).
Change in need for medication
The change in need for medication will be measured using an RM score (RMS), by comparing the baseline (Week 0) with the scores within treatment (Week 2, 3), end of treatment( Week 4) and post-treatment follow-up ( Week 8).

Full Information

First Posted
May 17, 2015
Last Updated
March 14, 2017
Sponsor
Hong Kong Baptist University
search

1. Study Identification

Unique Protocol Identification Number
NCT02470845
Brief Title
Trial of Tian Jiu Therapy for Allergic Rhinitis
Official Title
A Randomized Controlled Trial of Tian Jiu Therapy for Allergic Rhinitis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
September 2016 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hong Kong Baptist University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to investigate the efficacy and safety of Tian Jiu in the treatment of allergic rhinitis compared with placebo and waitlist patients in Hong Kong.
Detailed Description
This will be a prospective, randomized, single-blinded, controlled trial in patients with AR. After a one-week run-in period, eligible subjects will be randomly assigned to the Tian Jiu group, placebo-control group and waitlist-control group. The TJ and placebo-control groups will undergo a 4-week treatment with one session per week and one 4-week post-treatment follow-up. Participants in the waitlist-control group will not receive any treatment during the first 4 weeks but will be required to be assessed. The total study period will be nine weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Allergic Rhinitis (AR)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
136 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tian Jiu group
Arm Type
Experimental
Arm Description
The TJ group will undergo a 4-week treatment with herbal patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in the TJ group will be treated with herbal patches of Tian Jiu group on five acupoints on the back.
Arm Title
Placebo-control group
Arm Type
Sham Comparator
Arm Description
The placebo-control group will undergo a 4-week treatment with placebo patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in this group will be treated with placebo patches of placebo-control group on the same acupionts as the TJ group.
Arm Title
Waitlist-control group
Arm Type
No Intervention
Arm Description
The waitlist-control group will receive no treatment during the first 4 weeks but, beginning with the 5th week this group will receive TJ treatment for four weeks as compensatory.
Intervention Type
Drug
Intervention Name(s)
herbal patches of Tian Jiu group
Intervention Description
The formula of herbal patch consists of BaiJieZi (Sinapis Semen), Yan Hu Suo(CorydulisRhizoma)、ZhiGan Sui (Kansui Radix)、Xi Xin (Asari Radix et rhizama) and Rengong She xiang(Moschus Artifactus) . The four herbs will be ground into powder, mixed thoroughlywith 20% BaiJieZi (Sinapis Semen), 25% Yan Hu Suo(CorydulisRhizoma), 15% ZhiGan Sui (Kansui Radix), and 40% Xi Xin (Asari Radix et rhizama), and the mixed powder will mix with fresh ginger juice in the ratio of 20g to 25 ml. The mixture will be made to a patch weighted as 2g and 1cm*1cm round size. 0.02g artificial She Xiang (Moschus Artifactus) will be added on top of each patch. Each patch will be applied on one acupoint.
Intervention Type
Drug
Intervention Name(s)
placebo patches of placebo-control group
Intervention Description
The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm*1cm round size.Each patch will be applied on one acupoint.
Primary Outcome Measure Information:
Title
Change of total nasal symptom score
Description
The change in the weekly average of total nasal symptom score (TNSS) recorded in participants' diaries from baseline( Week 0) to end of the treatment( Week 4)and post-treatment follow-up ( Week 8)
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Change of the Rhinitis Quality of Life Questionnaire (RQLQ)
Description
The change in symptoms will be measured using the Rhinitis Quality of Life Questionnaire (RQLQ), by comparing the baseline( Week 0) with the scores within treatment (Week 2, 3), end of treatment( Week 4) and post-treatment follow-up ( Week 8).
Time Frame
8 weeks
Title
Change in need for medication
Description
The change in need for medication will be measured using an RM score (RMS), by comparing the baseline (Week 0) with the scores within treatment (Week 2, 3), end of treatment( Week 4) and post-treatment follow-up ( Week 8).
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Positive skin prick tests High circulating levels of allergen-specific IgE antibody detected by a specific blood test for allergy called radioallergosorbent test (RAST)] Clinical history or allergen to have been identified Nasal provocation (test) Exclusion Criteria: Allergic asthma, moderate to severe atopic dermatitis, autoimmune disorders, severe chronic inflammatory diseases, history of anaphylactic reactions, hypersensitivity to cetirizine or related drugs, specific immunotherapy during the past 3 years or planned in the next 2 years, pregnancy or breastfeeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhao Xiang Bian, Ph.D., M. D.
Organizational Affiliation
School of Chinese Medicine, Hong Kong Baptist University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hong Kong Baptist University Chinese Medicine Clinic
City
Hong Kong
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
27189087
Citation
Kun W, Zhong LL, Dai L, Cheng CW, Lu AP, Bian ZX. Tian Jiu therapy for allergic rhinitis: study protocol for a randomized controlled trial. Trials. 2016 May 17;17(1):248. doi: 10.1186/s13063-016-1374-5.
Results Reference
derived

Learn more about this trial

Trial of Tian Jiu Therapy for Allergic Rhinitis

We'll reach out to this number within 24 hrs